Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Cancer Res. 2017 Apr 20;77(12):3306–3316. doi: 10.1158/0008-5472.CAN-17-0298

Figure 5.

Figure 5

pdTp is non-toxic and inhibits human HCC xenografts. WT B6/CBA mice (2 months old) were injected i.p. with 0.8 mg/kg pdTp twice a week for 4 weeks. Body and liver weights (A), and serum liver enzymes (AST, ALT and AP), total protein (TP), albumin (Alb) and globulin (Glo) (B) were measured at the end of the treatment. C. Histology of internal organs at the end of pdTp treatment. D. QGY-7703 cells were injected s.c. in NSG mice to establish xenografts and treated with the indicated doses of pdTp i.p. twice a week for 4 weeks (n = 6 per dose). Tumor volume and weight were measured at the end of the treatment. E–F. QGY-luc cells were injected orthotopically in the livers of NSG mice to establish xenografts and treated with the indicated doses of pdTp i.v. twice a week for 4 weeks (n = 6 per dose). Bioluminescence imaging (BLI) of the orthotopic tumors before and after pdTp treatment (E). Quantification of photon counts from the mice (F). For graphs, data represent mean ± SEM; A, B and D: *: p<0.01 vs pdTp 0 mg/kg; F: *: p<0.05 vs pdTp 0 mg/kg After Rx.